NCT03225755View on ClinicalTrials.gov

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

CompletedOBSERVATIONAL
Enrollment

7

Participants

Timeline

Start Date

August 1, 2017

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions
Growth Hormone Deficiency
Interventions
DRUG

Growth hormone

Patients will receive growth hormone replacement therapy as per standard clinical care during this study.

Trial Locations (1)

10032

Neuroendocrine Unit and Pituitary Center, Columbia University, New York

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Columbia University

OTHER

NCT03225755 - Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy | Biotech Hunter | Biotech Hunter